Targeting combined MEK and HDAC inhibition as an effective therapeutic strategy for NF1 high-grade glioma

syn27261835

Created By review-service

dataType:
grantDOI: https://doi.org/10.48105/pc.gr.152655
keywords:
studyName: Targeting combined MEK and HDAC inhibition as an effective therapeutic strategy for NF1 high-grade glioma
dataStatus: Data Pending
initiative: Drug Discovery Initiative Registered Reports
studyLeads: Thomas De Raedt
studyStatus: Active
diseaseFocus: Neurofibromatosis type 1
grantEndDate: 1669766400000
institutions: Children's Hospital of Philadelphia
clinicalTrial:
fundingAgency: CTF
manifestation: High Grade Glioma
embargoEndDate: 1701302400000
grantStartDate: 1638316800000
relatedStudies: syn37889514 syn50315996 syn51207088 syn5698493
studyFileviewId: syn27261839
alternateDataRepository:
syn27261836
syn27261837
syn27261839
syn27261838

Your web browser must have JavaScript enabled in order for this application to display correctly.
If you are an automated web crawler from a search engine, follow this AJAX application crawl link

Targeting combined MEK and HDAC inhibition as an effective therapeutic strategy for NF1 high-grade glioma

syn27261835

Drop files to upload

Targeting combined MEK and HDAC inhibition as an effective therapeutic strategy for NF1 high-grade glioma page is loading…